Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research3

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research3

FiltersClear all

Status

Active, not recruiting3

Study type

Interventional3

Phase

Phase 33

Investigator

Evelyn Cantillo2
David Fishman1

Department

Obstetrics and Gynecology3

Condition

Fallopian Tube Neoplasms3
Breast Neoplasms17
Obesity15
COVID-1912
Overweight12

Show all 50

Intervention type

Drug3
Procedure1

Sponsor type

Industry2
Other academic1

Start date

Has results posted1

Phase 3×Fallopian Tube Neoplasms×Clear all

Showing 1–3 of 3 studiesSort:

Active, not recruitingInterventional · Phase 3NCT04095364 ↗
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

FiltersClear all

Status

Active, not recruiting3

Study type

Interventional3

Phase

Phase 33

Investigator

Evelyn Cantillo2
David Fishman1

Department

Obstetrics and Gynecology3

Condition

Fallopian Tube Neoplasms3
Breast Neoplasms17
Obesity15
COVID-1912
Overweight12

Show all 50

Intervention type

Drug3
Procedure1

Sponsor type

Industry2
Other academic1

Start date

Has results posted1

Phase 3×Fallopian Tube Neoplasms×Clear all

Showing 1–3 of 3 studiesSort:

Active, not recruitingInterventional · Phase 3NCT04095364 ↗
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Show fewer

Crohn Disease11
Prostatic Neoplasms9
Neoplasm Metastasis8
Colitis, Ulcerative7
Leukemia, Myeloid, Acute7
Lung Diseases, Interstitial7
Multiple Myeloma7
Carcinoma, Non-Small-Cell Lung6
Cardiovascular Diseases6
Hemophilia A6
Hypertension, Pulmonary6
Myelodysplastic Syndromes6
Non-alcoholic Fatty Liver Disease6
Atrial Fibrillation5
Liver Cirrhosis, Biliary5
Neoplasms5
Parkinson Disease5
Parkinson Disease 4, Autosomal Dominant Lewy Body5
Pulmonary Arterial Hypertension5
Pulmonary Disease, Chronic Obstructive5
Coronavirus Infections4
Dermatitis, Atopic4
Idiopathic Pulmonary Fibrosis4
Lung Neoplasms4
Metabolic Diseases4
Ovarian Neoplasms4
Adenocarcinoma Of Esophagus3
Amyloidosis3
Atherosclerosis3
Brain Neoplasms3
Burkitt Lymphoma3
Diabetes Mellitus, Type 23
Digestive System Diseases3
Endocrine System Diseases3
Eosinophilic Esophagitis3
Esophageal Squamous Cell Carcinoma3
Fibrosis3
Glioblastoma3
HIV Infections3
Heart Failure3
Hematologic Neoplasms3
Hypertension3
Inflammatory Bowel Diseases3
Ischemic Stroke3
Liver Diseases3

Evelyn CantilloPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Imaging Procedure · Drug: Letrozole · Drug: Paclitaxel
Dates: Sep 2019 – Feb 2027 (est.)
Sponsor: NRG Oncology

Low Grade Fallopian Tube Serous AdenocarcinomaOvarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous Adenocarcinoma+9 more

Active, not recruitingInterventional · Phase 3NCT05257408 ↗

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

David FishmanPI

Intervention: Drug: Relacorilant 150 mg · Drug: Nab-paclitaxel 80 mg/m^2 · Drug: Nab-paclitaxel 100 mg/m^2
Dates: Jun 2022 – Mar 2025· Results posted
Sponsor: Corcept Therapeutics Incorporated

Ovarian NeoplasmFallopian Tube NeoplasmsPeritoneal Neoplasms

Active, not recruitingInterventional · Phase 3NCT06619236 ↗

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Evelyn CantilloPI

Intervention: Drug: Rina-S · Drug: Paclitaxel · Drug: Topotecan · Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Gemcitabine
Dates: Feb 2025 – Aug 2026
Sponsor: GOG Foundation, Inc.

Platinum-resistant Ovarian Cancer

Browse

Browse

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer